Downstream Target Analysis for miR-365 among Oral Squamous Cell Carcinomas Reveals Differential Associations with Chemoresistance
Author:
Yu Brendon1, Kruse Nathaniel1, Howard Katherine M.2ORCID, Kingsley Karl2ORCID
Affiliation:
1. Department of Clinical Sciences, School of Dental Medicine, University of Nevada-Las Vegas, 1700 W. Charleston Boulevard, Las Vegas, NV 89106, USA 2. Department of Biomedical Sciences, School of Dental Medicine, University of Nevada-Las Vegas, 1001 Shadow Lane, Las Vegas, NV 89106, USA
Abstract
Expression of microRNAs, such as miR-365, is known to be dysregulated in many tumors, including oral cancers, although little is known about their role or functions. The objective of this project is to evaluate the downstream targets of miR-365 to determine any potential pathways or effects. Downstream targets for miR-365 (miRdatabase target scores > 90) were used for qPCR screening of oral cancer cell lines (SCC4, SCC9, SCC15, SCC25, CAL27). Each oral cancer cell line expressed miR-365 downstream targets molybdenum cofactor synthesis-2 (MOCS2), erythropoietin receptor (EPOR), IQ motif containing-K (IQCK), carboxypeptidase A3 (CPA3), solute carrier family 24 member-3 (SLC24A3), and coiled-coil domain containing 47 (CCDC47)—although the expression levels varied somewhat. However, differential results were observed with ubiquitin protein ligase E3 component n-recognin-3 (UBR3), nudix hydrolase-12 (NUDT12), zinc finger CCHC-type containing-14 (ZCCHC14), and homeobox and leucine zipper encoding (HOMEZ). These data suggest that many of the miR-365 targets are expressed in the oral cancers screened, with the differential expression of UBR3, ZCCHC14, HOMEZ, and NUDT12, which may be correlated with chemoresistance among two specific oral cancer cell lines (SCC25, SCC9). These results suggest this differential expression may signal potential targets for patient treatment with tumors exhibiting miR-365 and chemotherapeutic resistance.
Reference49 articles.
1. GBD 2019 Lip, Oral, and Pharyngeal Cancer Collaborators, Cunha, A.R.D., Compton, K., Xu, R., Mishra, R., Drangsholt, M.T., Antunes, J.L.F., Kerr, A.R., Acheson, A.R., and Lu, D. (2023). The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol., 9, 1401–1416. 2. Global Burden of Disease 2019 Cancer Collaboration, Kocarnik, J.M., Compton, K., Dean, F.E., Fu, W., Gaw, B.L., Harvey, J.D., Henrikson, H.J., Lu, D., and Pennini, A. (2022). Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol., 8, 420–444. 3. Survival of Young Versus Old Patients With Oral Cavity Squamous Cell Carcinoma: A Meta-Analysis;Lee;Laryngoscope,2021 4. The Impact of Dental Care in Head and Neck Cancer Outcomes: A Systematic Review and Meta-Analysis;Haynes;Laryngoscope,2022 5. Effectiveness of Interventions to Improve Oral Cancer Knowledge: A Systematic Review;Ahuja;J. Cancer Educ.,2022
|
|